With a totally redesigned appearance and format, Biotrial’s new website features up-to-date information on their expertise and capabilities including: Phase I, Phase II, proof of concept, targeted phase III, central laboratory, data management, biostatistics, and medical writing.

More visually appealing, the web site also allows visitors to take a “Virtual Tour” of the company’s state-of-the-art Phase I unit.

“Biotrial has experienced phenomenal growth since its foundation in 1989, it was time for a change,” said Jean-Marc Gandon, CEO. “Our goal was to have an internet presence that better reflects our success and where we are at the moment. We also wanted to make it easy for anyone interested in Biotrial to find the information they’re looking for in a clear and user-friendly manner. In addition to the comprehensive information of our experience and expertise, the web site also serves as a showcase for our 5000m2 corporate headquarters in Rennes. We found this to be especially helpful in answering the growing interest that the international market has in our company.”

Mr. Gandon concludes: “Biotrial clients include the top 10 pharmaceutical companies as well as small biotechs. We’ve gotten very positive feedback from all of them regarding our updated web site, which was very rewarding as Biotrial is always in tune to its clients and values their opinion.”

About Biotrial

Founded in 1989 by Jean-Marc Gandon, PharmD, (President & CEO), Biotrial is an independent and privately owned CRO.
With 150 beds and a staff of 250 in several subsidiaries in France and the UK, Biotrial runs over 80 studies per year, either in their own clinics in Paris and Rennes, or in cooperation with hospital specialists and general practitioners.
With a large range of services from Phase I studies, Clinical Trial Management Phase II-IV, Oncology, Data Management, Biostatistics, Central labs (ECG, MRI), Medical Writing, Non-Clinical Pharmacology, QA & advice in Regulatory Affairs, Biotrial can manage every step of your development process.